Fed Circuit won’t revisit Sanofi’s PTAB appeal despite Arthrex
30-01-2020
PTAB institutes IPRs on Sanofi patents
20-12-2017
nitpicker / Shutterstock.com
Pharmaceutical company Sanofi has been granted a stay by the US Supreme Court in its ongoing patent litigation battle with Netherlands-based Mylan over glargine (Lantus), a treatment for type 2 diabetes.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, SCOTUS, US Supreme Court, Lantus, patent, dispute, Mylan, glargine, type 2 diabetes
